SO YOUNG•Financial Summary•AI-Powered Insights

SO YOUNG 2025 Q2
Earnings Overview & AI Insights

Detailed performance report for SO YOUNG covering Q2 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

SO YOUNG (2025 Q2)

Earnings Performance

No Performance Data

Summary of Financial Performance:

  • Total Revenue: RMB 378.7 million, down 7% YoY, primarily due to reduced subscriptions from medical service providers.
  • Aesthetic Treatment Revenue: RMB 144.4 million, up 426.1% YoY, becoming the largest revenue segment and exceeding guidance.
  • Net Loss: RMB 36 million, reversing from net income of RMB 18.9 million YoY, attributed to business expansion costs.
  • Gross Profit Margin (Aesthetic Treatment): Improved by ~5 percentage points sequentially due to better operational efficiency.
  • Cash Position: Robust liquidity with RMB 998.6 million in cash and equivalents.

Company Outlook & Strategy:

  • Projected Q3 aesthetic treatment revenue: RMB 150-170 million, a YoY increase of 230.5%-274.6%.
  • Targeting 50 aesthetic centers by year-end 2025, expanding into tier-one and tier-two cities. Long-term goal: 1,000 centers within 8-10 years.
  • Pilot franchise rollout planned for Q4 2025 to evaluate scalability.
  • Continued focus on enhancing operational efficiency, customer loyalty, and recurring revenue streams.

Key Industry Trends:

  • China's medical aesthetics penetration rate is <5%, leaving ample growth potential compared to South Korea's >20%.
  • Light medical aesthetics projected to reach RMB 340 billion by 2030, with So-Young targeting a ~25% market share (~RMB 26 billion).
  • Increasing demand for standardized, light medical aesthetics services driven by anti-aging and personalized care.

Operational Highlights:

  • Active Users: >100,000 by June 2025, verified treatment visits up 381% YoY.
  • Repeat Purchase Rate: >60%, with high customer satisfaction (4.99/5).
  • Customer Acquisition Costs: Low, averaging RMB 100, with >70% of new customers sourced from private domain traffic and referrals.
  • Product Expansion: Launch of new treatments like Medical PLLA and Mermaid Skin Booster, boosting ARPU and portfolio differentiation.
  • Supply Chain Growth: 1,600 institutions served for injectables; Elasty shipments up >40% sequentially.

Challenges & Risks:

  • Revenue declines in subscription-based services (-35.6% YoY) and medical product sales (-28.1% YoY).
  • High competition in the Chinese medical aesthetics market, with new entrants posing challenges.
  • Net losses due to upfront costs associated with rapid network expansion and operational investments.

Key Analyst Questions & Responses:

  1. Expansion Plans: Management aims for 50 centers by 2025, with 1,000 centers targeted long-term. Franchising will be piloted in Q4 but remains secondary to self-operated centers due to manageable CapEx and shorter payback cycles.
  2. Market Growth Potential: China's medical aesthetics market remains under-penetrated (<5%), with light aesthetics poised for rapid growth. So-Young focuses on sustainable low-cost customer acquisition, supply chain scaling, and operational excellence.
  3. Customer Acquisition Costs: Expected to remain low due to private domain traffic and referrals. Increasing network density in key cities will further boost efficiency.
  4. Doctor Recruitment: Strong pipeline of qualified doctors from public hospitals ensures no bottlenecks. Nearly 90% of doctors specialize in dermatology, supported by standardized training.
  5. POP Business Synergy: Plans to integrate POP business with aesthetic centers by leveraging traffic and targeted merchant recommendations for non-standardized procedures.

Management Sentiment & Key Messages:

  • Positive and confident tone regarding growth potential and strategic execution.
  • Strong emphasis on operational efficiency, cost management, and customer-centric innovation.
  • Long-term vision centered around scaling the aesthetic center network while maintaining industry leadership.

This summary encapsulates the major insights from the earnings call and highlights the company's strategic direction, operational progress, and challenges ahead.

Earnings Call Transcript

Access the official earnings call transcript for SO-YOUNG 2025 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.